Clinical Trials Directory

Trials / Completed

CompletedNCT00871585

Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide

Non-interventional Observational Study to Evaluate Change of PSA Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide in Combination With Medical or Surgical Castration

Status
Completed
Phase
Study type
Observational
Enrollment
340 (actual)
Sponsor
AstraZeneca · Industry
Sex
Male
Age
40 Years
Healthy volunteers
Not accepted

Summary

Prospective, non-comparative, non-interventional, observational study to collect and analyse real life environment data on advanced prostate cancer patients receiving combination treatment of medical or surgical castration and bicalutamide according to routine medical practice in Croatia. The main aim is to evaluate change of PSA level and prescribing practices based on prostate cancer stage.

Conditions

Timeline

Start date
2009-03-01
Primary completion
2010-01-01
Completion
2010-01-01
First posted
2009-03-30
Last updated
2010-04-15

Locations

15 sites across 1 country: Croatia

Source: ClinicalTrials.gov record NCT00871585. Inclusion in this directory is not an endorsement.

Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide (NCT00871585) · Clinical Trials Directory